<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

November 8, 2019

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

AffyImmune Therapeutics announced FDA approval of their investigational new drug (IND) for AIC100, a CAR-T cell therapy aimed at treating patients with advanced thyroid cancer. The first-in-human phase I study will be sponsored by Weill Cornell Medical Center. Yourway is anticipating a surge in clinical trials exploring these advanced therapies, and is prepared to support any customers for their unique needs.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat
Come chat with us!
Hello! How can I help you?